1. Home
  2. NVAX vs AMPH Comparison

NVAX vs AMPH Comparison

Compare NVAX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • AMPH
  • Stock Information
  • Founded
  • NVAX 1987
  • AMPH 1996
  • Country
  • NVAX United States
  • AMPH United States
  • Employees
  • NVAX N/A
  • AMPH N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • AMPH Health Care
  • Exchange
  • NVAX Nasdaq
  • AMPH Nasdaq
  • Market Cap
  • NVAX 1.3B
  • AMPH 1.1B
  • IPO Year
  • NVAX 1995
  • AMPH 2014
  • Fundamental
  • Price
  • NVAX $6.84
  • AMPH $21.70
  • Analyst Decision
  • NVAX Buy
  • AMPH Hold
  • Analyst Count
  • NVAX 5
  • AMPH 5
  • Target Price
  • NVAX $16.60
  • AMPH $38.00
  • AVG Volume (30 Days)
  • NVAX 4.9M
  • AMPH 501.2K
  • Earning Date
  • NVAX 08-07-2025
  • AMPH 08-06-2025
  • Dividend Yield
  • NVAX N/A
  • AMPH N/A
  • EPS Growth
  • NVAX N/A
  • AMPH N/A
  • EPS
  • NVAX 2.97
  • AMPH 2.77
  • Revenue
  • NVAX $1,254,962,000.00
  • AMPH $730,659,000.00
  • Revenue This Year
  • NVAX $56.85
  • AMPH $0.67
  • Revenue Next Year
  • NVAX N/A
  • AMPH $5.18
  • P/E Ratio
  • NVAX $2.30
  • AMPH $7.83
  • Revenue Growth
  • NVAX 25.92
  • AMPH 8.05
  • 52 Week Low
  • NVAX $5.01
  • AMPH $21.48
  • 52 Week High
  • NVAX $17.81
  • AMPH $53.96
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.12
  • AMPH 28.01
  • Support Level
  • NVAX $6.54
  • AMPH $22.81
  • Resistance Level
  • NVAX $7.20
  • AMPH $23.77
  • Average True Range (ATR)
  • NVAX 0.28
  • AMPH 0.76
  • MACD
  • NVAX 0.06
  • AMPH -0.20
  • Stochastic Oscillator
  • NVAX 66.36
  • AMPH 9.27

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: